UY29298A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- UY29298A1 UY29298A1 UY29298A UY29298A UY29298A1 UY 29298 A1 UY29298 A1 UY 29298A1 UY 29298 A UY29298 A UY 29298A UY 29298 A UY29298 A UY 29298A UY 29298 A1 UY29298 A1 UY 29298A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- famraceutical
- medicine
- compositions
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula (I) o su derivado farmacéuticamente aceptable: en la que X, Y, Z, R2a, R2b, R3a, R3b, R8, R9 y Rx son tal como se define en la memoria, un procedimiento para la preparación de dichos compuestos, composiciones famracéuticas que comprenden dichos compuestos y el uso de dichos compuestos en medicina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0428263A GB0428263D0 (en) | 2004-12-23 | 2004-12-23 | Compounds |
GB0508458A GB0508458D0 (en) | 2005-04-26 | 2005-04-26 | Compounds |
GB0524675A GB0524675D0 (en) | 2005-12-02 | 2005-12-02 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29298A1 true UY29298A1 (es) | 2006-05-31 |
Family
ID=35735391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29298A UY29298A1 (es) | 2004-12-23 | 2005-12-21 | Compuestos |
Country Status (20)
Country | Link |
---|---|
US (2) | US20100137378A1 (es) |
EP (2) | EP1833795B1 (es) |
JP (1) | JP2008525363A (es) |
KR (1) | KR20070091301A (es) |
AR (1) | AR052429A1 (es) |
AT (1) | ATE424386T1 (es) |
AU (1) | AU2005318372A1 (es) |
BR (1) | BRPI0519398A2 (es) |
CA (1) | CA2592442A1 (es) |
DE (1) | DE602005013116D1 (es) |
EA (2) | EA200701324A1 (es) |
ES (1) | ES2321535T3 (es) |
IL (1) | IL183781A0 (es) |
MA (1) | MA29082B1 (es) |
MX (1) | MX2007007830A (es) |
NO (1) | NO20073332L (es) |
PE (2) | PE20060838A1 (es) |
TW (1) | TW200640865A (es) |
UY (1) | UY29298A1 (es) |
WO (1) | WO2006066968A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0608825D0 (en) * | 2006-05-04 | 2006-06-14 | Glaxo Group Ltd | Compounds |
CA2687764A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
FR2921062A1 (fr) * | 2007-09-17 | 2009-03-20 | Commissariat Energie Atomique | Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications |
EP2421835A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
EP2461809A4 (en) | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES |
SG178252A1 (en) | 2009-08-05 | 2012-03-29 | Panmira Pharmaceuticals Llc | Dp2 antagonist and uses thereof |
EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
TWI675827B (zh) | 2014-06-03 | 2019-11-01 | 瑞士商愛杜西亞製藥有限公司 | 吡唑化合物 |
WO2016057572A1 (en) | 2014-10-06 | 2016-04-14 | Mark Thomas Miller | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2017173274A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EA202192783A1 (ru) | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
BR112019011208A2 (pt) | 2016-12-16 | 2019-10-15 | Idorsia Pharmaceuticals Ltd | combinação farmacêutica, composição farmacêutica, e, kit de partes. |
JP6972144B2 (ja) | 2017-02-06 | 2021-11-24 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | 1−アリール−1−トリフルオロメチルシクロプロパンを合成するための新規な方法 |
AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
MX2020001302A (es) | 2017-08-02 | 2020-03-20 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina. |
TWI719349B (zh) | 2017-10-19 | 2021-02-21 | 美商維泰克斯製藥公司 | Cftr調節劑之結晶形式及組合物 |
CA3085006A1 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1471276A (en) | 1975-01-22 | 1977-04-21 | Nippon Shinyaku Co Ltd | 5-benzylpicolinic acid deri vatives |
EP0388682A1 (de) | 1989-03-15 | 1990-09-26 | Bayer Ag | Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
EP0738144A4 (en) | 1993-12-30 | 1999-06-30 | Smithkline Beecham Corp | PHENYLMETHYL HEXANAMIDES AND THEIR USE |
GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
ES2183935T3 (es) | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
DE69635254T2 (de) | 1995-07-07 | 2006-07-13 | Astrazeneca Ab | Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten |
UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
CN1098256C (zh) | 1996-04-12 | 2003-01-08 | G·D·瑟尔公司 | 作为cox-2抑制剂前药的取代的苯磺酰胺衍生物 |
EE03680B1 (et) | 1996-07-18 | 2002-04-15 | Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. | Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
YU11900A (sh) | 1997-09-05 | 2002-11-15 | Glaxo Group Limited | Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2) |
US6362009B1 (en) * | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
ES2228127T3 (es) | 1998-11-03 | 2005-04-01 | Glaxo Group Limited | Derivados de pirazolopiridina como inhibidores selectivos de cox-2. |
US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
ES2213601T3 (es) | 1999-09-14 | 2004-09-01 | MERCK FROSST CANADA & CO. | Acidos carboxilicos y acilsulfonamidas, composiciones que contienen tales compuestos y procedimiento de tratamiento. |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
JP2005522477A (ja) | 2002-04-08 | 2005-07-28 | グラクソ グループ リミテッド | (2−((2−アルコキシ)−フェニル)−シクロペント−1−エニル)芳香族炭素環式および複素環式酸および誘導体 |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
KR20050084890A (ko) | 2002-10-30 | 2005-08-29 | 머크 프로스트 캐나다 앤드 캄파니 | 피리도피롤리진 및 피리도인돌리진 유도체 |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
GB0306329D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Compounds |
GB0323585D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
GB0323581D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Novel compounds |
GB0323584D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
JP2007509104A (ja) | 2003-10-24 | 2007-04-12 | グラクソ グループ リミテッド | 複素環式化合物 |
GB0328024D0 (en) | 2003-12-03 | 2004-01-07 | Glaxo Group Ltd | Compounds |
GB0410121D0 (en) | 2004-05-06 | 2004-06-09 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-12-21 WO PCT/EP2005/014061 patent/WO2006066968A1/en active Application Filing
- 2005-12-21 EA EA200701324A patent/EA200701324A1/ru unknown
- 2005-12-21 EP EP05817767A patent/EP1833795B1/en active Active
- 2005-12-21 CA CA002592442A patent/CA2592442A1/en not_active Abandoned
- 2005-12-21 BR BRPI0519398-2A patent/BRPI0519398A2/pt not_active IP Right Cessation
- 2005-12-21 US US11/722,402 patent/US20100137378A1/en not_active Abandoned
- 2005-12-21 AT AT05817767T patent/ATE424386T1/de not_active IP Right Cessation
- 2005-12-21 DE DE602005013116T patent/DE602005013116D1/de active Active
- 2005-12-21 EA EA200801909A patent/EA200801909A1/ru unknown
- 2005-12-21 JP JP2007547393A patent/JP2008525363A/ja not_active Withdrawn
- 2005-12-21 TW TW094145424A patent/TW200640865A/zh unknown
- 2005-12-21 EP EP09150218A patent/EP2053042A1/en not_active Withdrawn
- 2005-12-21 MX MX2007007830A patent/MX2007007830A/es not_active Application Discontinuation
- 2005-12-21 UY UY29298A patent/UY29298A1/es unknown
- 2005-12-21 KR KR1020077014271A patent/KR20070091301A/ko not_active Application Discontinuation
- 2005-12-21 AR ARP050105412A patent/AR052429A1/es unknown
- 2005-12-21 ES ES05817767T patent/ES2321535T3/es active Active
- 2005-12-21 AU AU2005318372A patent/AU2005318372A1/en not_active Abandoned
-
2006
- 2006-01-03 PE PE2006000025A patent/PE20060838A1/es not_active Application Discontinuation
- 2006-01-30 PE PE2008001431A patent/PE20081440A1/es not_active Application Discontinuation
-
2007
- 2007-06-06 MA MA29966A patent/MA29082B1/fr unknown
- 2007-06-07 IL IL183781A patent/IL183781A0/en unknown
- 2007-06-21 US US11/766,418 patent/US7759369B2/en not_active Expired - Fee Related
- 2007-06-28 NO NO20073332A patent/NO20073332L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2053042A1 (en) | 2009-04-29 |
JP2008525363A (ja) | 2008-07-17 |
PE20081440A1 (es) | 2008-12-31 |
IL183781A0 (en) | 2007-09-20 |
EP1833795B1 (en) | 2009-03-04 |
EA200701324A1 (ru) | 2007-10-26 |
MA29082B1 (fr) | 2007-12-03 |
EA200801909A1 (ru) | 2009-06-30 |
BRPI0519398A2 (pt) | 2009-01-20 |
EP1833795A1 (en) | 2007-09-19 |
KR20070091301A (ko) | 2007-09-10 |
US20080249138A1 (en) | 2008-10-09 |
AR052429A1 (es) | 2007-03-21 |
US20100137378A1 (en) | 2010-06-03 |
CA2592442A1 (en) | 2006-06-29 |
US7759369B2 (en) | 2010-07-20 |
DE602005013116D1 (de) | 2009-04-16 |
ATE424386T1 (de) | 2009-03-15 |
PE20060838A1 (es) | 2006-10-12 |
NO20073332L (no) | 2007-09-17 |
WO2006066968A1 (en) | 2006-06-29 |
TW200640865A (en) | 2006-12-01 |
ES2321535T3 (es) | 2009-06-08 |
AU2005318372A1 (en) | 2006-06-29 |
MX2007007830A (es) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29298A1 (es) | Compuestos | |
DOP2009000124A (es) | Derivados de benzamida como receptores agonista ep4 | |
UY29002A1 (es) | Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
DOP2010000323A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
UY31215A1 (es) | Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia. | |
UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
CL2009002206A1 (es) | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. | |
NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
UY29896A1 (es) | Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
ECSP10010197A (es) | Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular | |
DOP2002000433A (es) | 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso | |
UY27571A1 (es) | 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso | |
ECSP10010636A (es) | El uso de partículas transportadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
CL2011000917A1 (es) | Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias. | |
CR10095A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
UY30195A1 (es) | Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones | |
TW200503998A (en) | Phenyl compounds | |
ECSP066588A (es) | Tiazolidinonas, su preparación y su uso como medicamentos |